562 related articles for article (PubMed ID: 27098021)
1. Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.
Gray GE; Mayer KH; Elizaga ML; Bekker LG; Allen M; Morris L; Montefiori D; De Rosa SC; Sato A; Gu N; Tomaras GD; Tucker T; Barnett SW; Mkhize NN; Shen X; Downing K; Williamson C; Pensiero M; Corey L; Williamson AL
Clin Vaccine Immunol; 2016 Jun; 23(6):496-506. PubMed ID: 27098021
[TBL] [Abstract][Full Text] [Related]
2. Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.
Churchyard G; Mlisana K; Karuna S; Williamson AL; Williamson C; Morris L; Tomaras GD; De Rosa SC; Gilbert PB; Gu N; Yu C; Mkhize NN; Hermanus T; Allen M; Pensiero M; Barnett SW; Gray G; Bekker LG; Montefiori DC; Kublin J; Corey L
PLoS One; 2016; 11(9):e0161753. PubMed ID: 27583368
[TBL] [Abstract][Full Text] [Related]
3. Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.
Viegas EO; Tembe N; Nilsson C; Meggi B; Maueia C; Augusto O; Stout R; Scarlatti G; Ferrari G; Earl PL; Wahren B; Andersson S; Robb ML; Osman N; Biberfeld G; Jani I; Sandström E
AIDS Res Hum Retroviruses; 2018 Feb; 34(2):193-205. PubMed ID: 28969431
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
[TBL] [Abstract][Full Text] [Related]
5. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.
Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049
[TBL] [Abstract][Full Text] [Related]
6. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Bråve A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandström E; Wahren B
PLoS One; 2015; 10(6):e0131748. PubMed ID: 26121679
[TBL] [Abstract][Full Text] [Related]
7. Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.
Joachim A; Bauer A; Joseph S; Geldmacher C; Munseri PJ; Aboud S; Missanga M; Mann P; Wahren B; Ferrari G; Polonis VR; Robb ML; Weber J; Tatoud R; Maboko L; Hoelscher M; Lyamuya EF; Biberfeld G; Sandström E; Kroidl A; Bakari M; Nilsson C; McCormack S
PLoS One; 2016; 11(5):e0155702. PubMed ID: 27192151
[TBL] [Abstract][Full Text] [Related]
8. Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus.
van Diepen MT; Chapman R; Douglass N; Galant S; Moore PL; Margolin E; Ximba P; Morris L; Rybicki EP; Williamson AL
J Virol; 2019 Apr; 93(8):. PubMed ID: 30760570
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain.
Lian Y; Srivastava I; Gómez-Román VR; Zur Megede J; Sun Y; Kan E; Hilt S; Engelbrecht S; Himathongkham S; Luciw PA; Otten G; Ulmer JB; Donnelly JJ; Rabussay D; Montefiori D; van Rensburg EJ; Barnett SW
J Virol; 2005 Nov; 79(21):13338-49. PubMed ID: 16227256
[TBL] [Abstract][Full Text] [Related]
10. Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.
Cox JH; Ferrari MG; Earl P; Lane JR; Jagodzinski LL; Polonis VR; Kuta EG; Boyer JD; Ratto-Kim S; Eller LA; Pham DT; Hart L; Montefiori D; Ferrari G; Parrish S; Weiner DB; Moss B; Kim JH; Birx D; VanCott TC
Vaccine; 2012 Feb; 30(10):1830-40. PubMed ID: 22234262
[TBL] [Abstract][Full Text] [Related]
11. Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.
Viegas EO; Kroidl A; Munseri PJ; Missanga M; Nilsson C; Tembe N; Bauer A; Joachim A; Joseph S; Mann P; Geldmacher C; Fleck S; Stöhr W; Scarlatti G; Aboud S; Bakari M; Maboko L; Hoelscher M; Wahren B; Robb ML; Weber J; McCormack S; Biberfeld G; Jani IV; Sandström E; Lyamuya E;
PLoS One; 2018; 13(11):e0206838. PubMed ID: 30496299
[TBL] [Abstract][Full Text] [Related]
12. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.
Bakari M; Aboud S; Nilsson C; Francis J; Buma D; Moshiro C; Aris EA; Lyamuya EF; Janabi M; Godoy-Ramirez K; Joachim A; Polonis VR; Bråve A; Earl P; Robb M; Marovich M; Wahren B; Pallangyo K; Biberfeld G; Mhalu F; Sandström E
Vaccine; 2011 Oct; 29(46):8417-28. PubMed ID: 21864626
[TBL] [Abstract][Full Text] [Related]
13. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.
Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963
[TBL] [Abstract][Full Text] [Related]
14. Regulatory T cell abundance and activation status before and after priming with HIVIS-DNA and boosting with MVA-HIV/rgp140/GLA-AF may impact the magnitude of the vaccine-induced immune responses.
Chissumba RM; Luciano A; Namalango E; Bauer A; Bhatt N; Wahren B; Nilsson C; Geldmacher C; Scarlatti G; Jani I; Kestens L;
Immunobiology; 2018 Dec; 223(12):792-801. PubMed ID: 30121146
[TBL] [Abstract][Full Text] [Related]
15. Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers.
Joachim A; Munseri PJ; Nilsson C; Bakari M; Aboud S; Lyamuya EF; Tecleab T; Liakina V; Scarlatti G; Robb ML; Earl PL; Moss B; Wahren B; Mhalu F; Ferrari G; Sandstrom E; Biberfeld G
AIDS Res Hum Retroviruses; 2017 Aug; 33(8):880-888. PubMed ID: 28027665
[TBL] [Abstract][Full Text] [Related]
16. Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.
Nilsson C; Godoy-Ramirez K; Hejdeman B; Bråve A; Gudmundsdotter L; Hallengärd D; Currier JR; Wieczorek L; Hasselrot K; Earl PL; Polonis VR; Marovich MA; Robb ML; Sandström E; Wahren B; Biberfeld G
AIDS Res Hum Retroviruses; 2014 Mar; 30(3):299-311. PubMed ID: 24090081
[TBL] [Abstract][Full Text] [Related]
17. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).
Churchyard GJ; Morgan C; Adams E; Hural J; Graham BS; Moodie Z; Grove D; Gray G; Bekker LG; McElrath MJ; Tomaras GD; Goepfert P; Kalams S; Baden LR; Lally M; Dolin R; Blattner W; Kalichman A; Figueroa JP; Pape J; Schechter M; Defawe O; De Rosa SC; Montefiori DC; Nabel GJ; Corey L; Keefer MC;
PLoS One; 2011; 6(8):e21225. PubMed ID: 21857901
[TBL] [Abstract][Full Text] [Related]
18. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
Stephenson KE; Wegmann F; Tomaka F; Walsh SR; Tan CS; Lavreys L; Ansel JL; Kanjilal DG; Jaegle K; Nkolola JP; Peter L; Fogel R; Bradshaw C; Tyler A; Makoni T; Howe L; Quijada D; Chandrashekar A; Bondzie EA; Borducchi EN; Yanosick KE; Hendriks J; Nijs S; Truyers C; Tolboom J; Zahn RC; Seaman MS; Alter G; Stieh DJ; Pau MG; Schuitemaker H; Barouch DH
Lancet HIV; 2020 Jun; 7(6):e410-e421. PubMed ID: 32078815
[TBL] [Abstract][Full Text] [Related]
19. Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection.
Ditse Z; Mkhize NN; Yin M; Keefer M; Montefiori DC; Tomaras GD; Churchyard G; Mayer KH; Karuna S; Morgan C; Bekker LG; Mlisana K; Gray G; Moodie Z; Gilbert P; Moore PL; Williamson C; Morris L
mSphere; 2020 Jan; 5(1):. PubMed ID: 31996422
[TBL] [Abstract][Full Text] [Related]
20. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
